Roberta Alfieri

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 14

Top Topics

Epidermal Growth Factor Receptor

Ejection Fraction

Positive Breast Cancer

Small Cell Lung Cancer

Top Venues

International journal of molecular sciences

Journal of experimental & clinical cancer research : CR

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Pia Adorni, Maricla Galetti, Silvia La Monica, Matteo Incerti, Alessandro Ruffoni, Lisa Elviri, Ilaria Zanotti, Bianca Papotti, Delia Cavallo, Roberta Alfieri, Pier Giorgio Petronini, Franco Bernini
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International journal of molecular sciences 24 (2) (2023)
Maria Pia Adorni, Maricla Galetti, Silvia La Monica, Matteo Incerti, Alessandro Ruffoni, Lisa Elviri, Ilaria Zanotti, Bianca Papotti, Delia Cavallo, Roberta Alfieri, Pier Giorgio Petronini, Franco Bernini
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International journal of molecular sciences 24 (2) (2023)
Maria Pia Adorni, Maricla Galetti, Silvia La Monica, Matteo Incerti, Alessandro Ruffoni, Lisa Elviri, Ilaria Zanotti, Bianca Papotti, Delia Cavallo, Roberta Alfieri, Pier Giorgio Petronini, Franco Bernini
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International journal of molecular sciences 24 (2) (2023)
Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells. Cancers 14 (23) (2022)
Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells. Cancers 14 (23) (2022)
Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells. Cancers 14 (23) (2022)
Kamal Eltayeb, Silvia La Monica, Marcello Tiseo, Roberta Alfieri, Claudia Fumarola
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer. Cells 11 (3) (2022)
Maicol Mancini, Quentin-Dominique Thomas, Sylvia Bourdel, Laura Papon, Emilie Bousquet, Prisca Jalta, Silvia La Monica, Camille Travert, Roberta Alfieri, Xavier Quantin, Marta Cañamero, Antonio Maraver
Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. Cancers 13 (14) (2021)
Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Roberta Alfieri, Mara Bonelli
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma. Cancers 13 (11) (2021)
Valentina Cocce, Silvia La Monica, Mara Bonelli, Giulio Alessandri, Roberta Alfieri, Costanza Annamaria Lagrasta, Denise Madeddu, Caterina Frati, Lisa Flammini, Daniela Lisini, Angela Marcianti, Eugenio Parati, Francesca Paino, Aldo Bruno Gianni, Giampietro Farronato, Angela Falco, Lorenzo Spaggiari, Francesco Petrella, Augusto Pessina
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells. Cells 10 (6) (2021)
Silvia La Monica, Claudia Fumarola, Daniele Cretella, Mara Bonelli, Roberta Minari, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Francesco Volta, Maicol Mancini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers 13 (1) (2020)
Mara Bonelli, Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Silvia La Monica, Daniele Cretella, Roberta Alfieri, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Pier Giorgio Petronini
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. International journal of molecular sciences 21 (14) (2020)
Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Denise Madeddu, Angela Falco, Costanza Annamaria Lagrasta, Anna Squadrilli, Elisabetta Barocelli, Alessandro Romanel, Federico Quaini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of experimental & clinical cancer research : CR 38 (1) (2019)
Silvia La Monica, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Graziana Digiacomo, Lisa Flammini, Elisabetta Barocelli, Roberta Minari, Nadia Naldi, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. Journal of experimental & clinical cancer research : CR 36 (1) (2017)